ICML 2023 | Using GEP to molecularly characterize & predict the outcomes of patients with PMBCL
Vincent Camus, MD, University of Rouen, Rouen, France, shares some insights into the biology of primary mediastinal large B-cell lymphoma (PMBCL), and discusses the results of a study which used gene expression profiling (GEP) to molecularly characterize and identify patients that may have a poorer outcome with first-line chemoimmunotherapy. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultant or advisory role: Roche, BMS, Novartis, Kite-Gilead, Janssen, Abbvie, Sanofi, Octapharma, Kyowa Kirin Pharma
Research funding: Iqone Healthcare, BMS
Educational grants: Pfizer, Roche, BMS, Novartis, Kite-Gilead
